AF03, An Alternative Squalene Emulsion‐Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature Method

Klucker, Marie-Francoise; Dalençon, François; Probeck, Patricia; Haensler, Jean

doi:10.1002/jps.23311

Cited by 70 publications

(39 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies suggested that, to improve distribution of polymeric NPs into the brain tissue, surface modification should be performed with high densities of PEG [29, 44]. The squalene molecule itself presents tensioactive properties and has been used as an emulsion adjuvant for vaccines [46], and the squalenoyl prodrugs have been shown to retain these properties [47]. Accordingly, we observed that low PEG densities could be sufficient to confer stability of NPs in interstitial fluid (Fig.…”

Section: Resultsmentioning

confidence: 59%

PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma

et al. 2016

View full text Add to dashboard Cite

New treatments for glioblastoma multiforme (GBM) are desperately needed, as GBM prognosis remains poor, mainly due to treatment resistance, poor distribution of therapeutics in the tumor tissue, and fast metabolism of chemotherapeutic drugs in the brain extracellular space. Convection-enhanced delivery (CED) of nanoparticles (NPs) has been shown to improve the delivery of chemotherapeutic drugs to the tumor bed, providing sustained release, and enhancing survival of animals with intracranial tumors. Here we administered gemcitabine, a nucleoside analog used as a first line treatment for a wide variety of extracranial solid tumors, within squalene-based NPs using CED, to overcome the above-mentioned challenges of GBM treatment. Small percentages of poly(ethylene) glycol (PEG) dramatically enhanced the distribution of squalene-gemcitabine nanoparticles (SQ-Gem NPs) in healthy animals and tumor-bearing animals after administration by CED. When tested in an orthotopic model of GBM, SQ-Gem-PEG NPs demonstrated significantly improved therapeutic efficacy compared to free gemcitabine, both as a chemotherapeutic drug and as a radiosensitizer. Furthermore, MR contrast agents were incorporated into the SQ-Gem NP formulation, providing a way to non-invasively track the NPs during infusion.

show abstract

Section: Resultsmentioning

confidence: 59%

PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The manufacture of AF03 is slightly different to MF59 and AS03, using phase inversion temperature emulsification process 72 . But since it is also an oil-in-water adjuvant it is likely to have a similar mechanism of action to other oil-in-water adjuvants.…”

Section: As03mentioning

confidence: 99%

Adjuvanted influenza vaccines

Tregoning

Russell

Kinnear

2018

Human Vaccines & Immunotherapeutics

216

194

View full text Add to dashboard Cite

“…Emulsions approved for clinical use, such as MF59, AF03 and AS03 [56][57][58], are liquid droplets dispersed throughout an immiscible liquid. This class includes oil-in-water and water-in-oil emulsions.…”

Section: Emulsionmentioning

confidence: 99%

On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives

Pellegrino

Clementi

Radice

2015

Autoimmunity Reviews

View full text Add to dashboard Cite

AF03, An Alternative Squalene Emulsion‐Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature Method

Cited by 70 publications

References 38 publications

PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma

PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma

Adjuvanted influenza vaccines

On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives

Contact Info

Product

Resources

About